Advertisement

Virologica Sinica

, Volume 34, Issue 1, pp 88–96 | Cite as

Electroporation-Mediated Immunization of a Candidate DNA Vaccine Expressing Dengue Virus Serotype 4 prM-E Antigen Confers Long-Term Protection in Mice

  • Ziyang Sheng
  • Hui Chen
  • Kaihao Feng
  • Na Gao
  • Ran Wang
  • Peigang Wang
  • Dongying Fan
  • Jing AnEmail author
Research article

Abstract

Dengue fever, caused by dengue viruses (DENVs), is a widespread mosquito-borne zoonotic disease; however, there is no available anti-dengue vaccine for worldwide use. In the current study, a DNA vaccine candidate (pV-D4ME) expressing prM-E protein of DENV serotype 4 (DENV-4) was constructed, and its immunogenicity and protection were evaluated in immunocompetent BALB/c mice. The pV-D4ME candidate vaccine induced effective humoral and cellular immunity of mice against DENV-4 in vivo when administered both at 50 μg and 5 μg through electroporation. Two weeks after receiving three immunizations, both doses of pV-D4ME DNA were shown to confer effective protection against lethal DENV-4 challenge. Notably, at 6 months after the three immunizations, 50 μg, but not 5 μg, of pV-D4ME could provide stable protection (100% survival rate) against DENV-4 lethal challenge without any obvious clinical signs. These results suggest that immunization with 50 μg pV-D4ME through electroporation could confer effective and long-term protection against DENV-4, offering a promising approach for development of a novel DNA vaccine against DENVs.

Keywords

Dengue virus (DENV) DNA vaccine Long-term protection Electroporation Mouse 

Notes

Acknowledgements

This work was supported by the National Natural Science Foundation of China (81772172, 81471957, 81671971, U1602223).

Author Contributions

ZS, HC, KF, NG, DF performed the experiments. RW and PW analyzed the data. JA organized the collaboration and prepared the manuscript. All authors read and approved the final manuscript.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Animal and Human Rights Statement

The whole study was approved by the Institutional Animal Care and Use Committee of Capital Medical University, China (Approval Number: AEEI-2015-066). All institutional and national guidelines for the care and use of laboratory animals were followed.

References

  1. Babiuk S, Baca-Estrada ME, Foldvari M, Middleton DM, Rabussay D, Widera G, Babiuk LA (2004) Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J Biotechnol 110:1–10CrossRefGoogle Scholar
  2. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI (2013) The global distribution and burden of dengue. Nature 496:504–507CrossRefGoogle Scholar
  3. Chen H, Gao N, Fan D, Wu J, Zhu J, Li J, Wang J, Chen Y, An J (2012) Suppressive effects on the immune response and protective immunity to a JEV DNA vaccine by co-administration of a GM-CSF-expressing plasmid in mice. PLoS ONE 7:e34602CrossRefGoogle Scholar
  4. Chen H, Zheng X, Wang R, Gao N, Sheng Z, Fan D, Feng K, Liao X, An J (2016) Immunization with electroporation enhances the protective effect of a DNA vaccine candidate expressing prME antigen against dengue virus serotype 2 infection. Clin Immunol 171:41–49CrossRefGoogle Scholar
  5. Clements DE, Coller BA, Lieberman MM, Ogata S, Wang G, Harada KE, Putnak JR, Ivy JM, McDonell M, Bignami GS, Peters ID, Leung J, Weeks-Levy C, Nakano ET, Humphreys T (2010) Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 28:2705–2715CrossRefGoogle Scholar
  6. Dai Z, Huang J, Lei X, Yan Y, Lu P, Zhang H, Lin W, Chen W, Ma J, Xie Q (2017) Efficacy of an autophagy-targeted DNA vaccine against avian leukosis virus subgroup. J. Vaccine 35:808–813CrossRefGoogle Scholar
  7. Fatima K, Syed NI (2018) Dengvaxia controversy: impact on vaccine hesitancy. J Glob Health 8:010312CrossRefGoogle Scholar
  8. Griffin BD, Muthumani K, Warner BM, Majer A, Hagan M, Audet J, Stein DR, Ranadheera C, Racine T, De La Vega MA, Piret J, Kucas S, Tran KN, Frost KL, De Graff C, Soule G, Scharikow L, Scott J, McTavish G, Smid V, Park YK, Maslow JN, Sardesai NY, Kim JJ, Yao XJ, Bello A, Lindsay R, Boivin G, Booth SA, Kobasa D, Embury-Hyatt C, Safronetz D, Weiner DB, Kobinger GP (2017) DNA vaccination protects mice against Zika virus-induced damage to the testes. Nat Commun 8:15743CrossRefGoogle Scholar
  9. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, Hunsperger E, Kroeger A, Margolis HS, Martinez E, Nathan MB, Pelegrino JL, Simmons C, Yoksan S, Peeling RW (2010) Dengue: a continuing global threat. Nat Rev Microbiol 8:S7–16CrossRefGoogle Scholar
  10. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, Tran HN, Bouckenooghe A, Chansinghakul D, Cortes M, Fanouillere K, Forrat R, Frago C, Gailhardou S, Jackson N, Noriega F, Plennevaux E, Wartel TA, Zambrano B, Saville M, Group C-TDVW (2015) Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373:1195–1206CrossRefGoogle Scholar
  11. Halstead SB (2016) Dengue vaccine efficacy: not a zero sum game. J Infect Dis 214:2014CrossRefGoogle Scholar
  12. Heinz FX, Stiasny K, Puschner-Auer G, Holzmann H, Allison SL, Mandl CW, Kunz C (1994) Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM. Virology 198:109–117CrossRefGoogle Scholar
  13. Hirao LA, Wu L, Khan AS, Satishchandran A, Draghia-Akli R, Weiner DB (2008) Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 26:440–448CrossRefGoogle Scholar
  14. Huang T, Zhao K, Zhang Z, Tang C, Zhang X, Yue B (2016) DNA vaccination based on pyolysin co-immunized with IL-1beta enhances host antibacterial immunity against Trueperella pyogenes infection. Vaccine 34:3469–3477CrossRefGoogle Scholar
  15. Hutnick NA, Myles DJ, Bian CB, Muthumani K, Weiner DB (2011) Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Curr Opin Virol 1:233–240CrossRefGoogle Scholar
  16. Khan KH (2013) DNA vaccines: roles against diseases. Germs 3:26–35CrossRefGoogle Scholar
  17. Kim D, Hung CF, Wu TC, Park YM (2010) DNA vaccine with alpha-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells. Vaccine 28:7297–7305CrossRefGoogle Scholar
  18. Lambricht L, Lopes A, Kos S, Sersa G, Preat V, Vandermeulen G (2016) Clinical potential of electroporation for gene therapy and DNA vaccine delivery. Expert Opin Drug Deliv 13:295–310CrossRefGoogle Scholar
  19. Liu MA (2011) DNA vaccines: an historical perspective and view to the future. Immunol Rev 239:62–84CrossRefGoogle Scholar
  20. Livingston BD, Little SF, Luxembourg A, Ellefsen B, Hannaman D (2010) Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques. Vaccine 28:1056–1061CrossRefGoogle Scholar
  21. Ocazionez Jimenez R, Lopes da Fonseca BA (2000) Recombinant plasmid expressing a truncated dengue-2 virus E protein without co-expression of prM protein induces partial protection in mice. Vaccine 19:648–654CrossRefGoogle Scholar
  22. Pang T, Mak TK, Gubler DJ (2017) Prevention and control of dengue-the light at the end of the tunnel. Lancet Infect Dis 17:e79–e87CrossRefGoogle Scholar
  23. Porter KR, Raviprakash K (2015) Nucleic acid (DNA) immunization as a platform for dengue vaccine development. Vaccine 33:7135–7140CrossRefGoogle Scholar
  24. Ranjit S, Kissoon N (2011) Dengue hemorrhagic fever and shock syndromes. Pediatr Crit Care Med 12:90–100CrossRefGoogle Scholar
  25. Rigau-Perez JG, Clark GG, Gubler DJ, Reiter P, Sanders EJ, Vorndam AV (1998) Dengue and dengue haemorrhagic fever. Lancet 352:971–977CrossRefGoogle Scholar
  26. Sardesai NY, Weiner DB (2011) Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 23:421–429CrossRefGoogle Scholar
  27. Sheng Z, Gao N, Cui X, Fan D, Chen H, Wu N, Wei J, An J (2016) Electroporation enhances protective immune response of a DNA vaccine against Japanese encephalitis in mice and pigs. Vaccine 34:5751–5757CrossRefGoogle Scholar
  28. Stachyra A, Gora-Sochacka A, Sirko A (2014) DNA vaccines against influenza. Acta Biochim Pol 61:515–522Google Scholar
  29. Suschak JJ, Wang S, Fitzgerald KA, Lu S (2015) Identification of Aim2 as a sensor for DNA vaccines. J Immunol 194:630–636CrossRefGoogle Scholar
  30. Wei J, Chen H, An J (2014) Recent progress in dengue vaccine development. Virol Sin 29:353–363CrossRefGoogle Scholar
  31. Weiland O, Ahlen G, Diepolder H, Jung MC, Levander S, Fons M, Mathiesen I, Sardesai NY, Vahlne A, Frelin L, Sallberg M (2013) Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C. Mol Ther 21:1796–1805CrossRefGoogle Scholar
  32. WHO (2016) Questions and answers on dengue vaccines. https://www.who.int/immunization/research/development/dengue_q_and_a/en/. Last updated 20 April 2018
  33. WHO (2017) Dengue vaccine: WHO position paper, July 2016—recommendations. Vaccine 35:1200–1201CrossRefGoogle Scholar
  34. Yang B, Jeang J, Yang A, Wu TC, Hung CF (2014) DNA vaccine for cancer immunotherapy. Hum Vaccines Immunother 10:3153–3164CrossRefGoogle Scholar
  35. Yauch LE, Shresta S (2014) Dengue virus vaccine development. Adv Virus Res 88:315–372CrossRefGoogle Scholar
  36. Zellweger RM, Miller R, Eddy WE, White LJ, Johnston RE, Shresta S (2013) Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog 9:e1003723CrossRefGoogle Scholar
  37. Zheng X, Chen H, Wang R, Fan D, Feng K, Gao N, An J (2017) Effective protection induced by a monovalent DNA vaccine against dengue virus (DV) serotype 1 and a bivalent DNA vaccine against DV1 and DV2 in mice. Front Cell Infect Microbiol 7:175CrossRefGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS 2019

Authors and Affiliations

  1. 1.Department of Microbiology, School of Basic Medical SciencesCapital Medical UniversityBeijingChina
  2. 2.Center of EpilepsyBeijing Institute for Brain DisordersBeijingChina

Personalised recommendations